TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Geriatric Resources for Assessment and Care of Elders
Brief Summary: The purpose of this study is to test the effectiveness of a collaborative model of team care as compared to usual care in improving functional outcomes among community-dwelling low-income older adults.


Options:
A: Hospitalizations: rates of first hospitalization, number and reason (Three years)
B: Functional status; health status; hospitalization and nursing home placement
C: Progress attaining health goals (12 months)
D: Health care utilization including EMR, hospital admissions, care days, out patient hospital or primary care (Change from 1 year before inclusion to 1 year follow up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Dietary Energy Restriction and Metabolic Aging in Humans
Brief Summary: The purpose of this study is to develop an effective calorie restricted diet.


Options:
A: Revised QUICKI (RQUICKI) (Baseline); RQUICKI (day 29); RQUICKI (day 31)
B: Changes in body weight, body fatness and total energy expenditure at baseline, 3, 6, and 12 months of caloric restriction (CR).
C: Decrease in high sensitivity C-reactive protein (hsCRP) (16 weeks-- Baseline, 8 weeks, 16 weeks)
D: Change in Glucose Tolerance (Before and after 5 weeks on each feeding schedule)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Trial of Proximity Alarms to Reduce Patient Falls
Brief Summary: The purpose of this study is to test an intervention to introduce and implement proximity alarms on the risk of falls in hospitalized patients.


Options:
A: Patient falls over 15 months
B: Risk of fall (3 months)
C: Fall Related Process Measures (6 months post intervention)
D: Number of LTC residents on vitamin D (16 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Hospital-based Brief Intervention for Alcohol Problems
Brief Summary: The objective of this project was to test whether screening and brief intervention for unhealthy alcohol use leads to improved alcohol-related outcomes (such as alcohol consumption and linkage to alcohol assistance) and is cost-effective.


Options:
A: Change in alcohol consumption Score as assessed by the AUDIT-C tool . (6 months)
B: alcohol use (6 months); HIV risk taking (6 months)
C: Linkage to alcohol assistance; Change in drinks per day
D: Drinks per drinking day (6 months); Rate of effective contraception (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Hospital-based Brief Intervention for Alcohol Problems
Brief Summary: The objective of this project was to test whether screening and brief intervention for unhealthy alcohol use leads to improved alcohol-related outcomes (such as alcohol consumption and linkage to alcohol assistance) and is cost-effective.


Options:
A: Linkage to alcohol assistance; Change in drinks per day
B: Primary outcome variables include alcohol misuse and violent behaviors. (12-months)
C: Discontinuation of consumption of prescription drugs (one year); Reduction of consumption of prescription drugs (one year); Utilization of formal help (one year)
D: alcohol use (6 months); HIV risk taking (6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Gabapentin as an Adjunct to Naltrexone for Alcoholism
Brief Summary: The purpose of this study is to determine whether, after a period of abstinence, adding 6 weeks of gabapentin (a medication approved to treat seizures) to a standard 16-week naltrexone (an opiate blocking agent approved for the treatment of alcohol dependence) treatment protocol is helpful in decreasing relapse to drinking compared to naltrexone alone or placebo. All participants will receive alcohol counseling.


Options:
A: Percent days abstinent; Time to relapse to heavy drinking
B: The change in percentage of heavy drinking days (5 or more standard drinking units per day for men and 4 or more standard drinking units per day for women) from baseline at 12 weeks or final visit.
C: Time to Relapse to Drinking (16 weeks)
D: Standard Alcoholic Drinks Per Treatment Period (During each 14 day treatment period)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Short-term Versus Long-term Treatment in Generalized Anxiety Disorder
Brief Summary: This study will assess the effectiveness of venlafaxine XR, randomized to either venlafaxine XR or placebo in preventing the relapse of generalized anxiety disorder after 6 months of treatment versus 12 months of treatment.


Options:
A: Number of Participants in Remission According to the Longitudinal Interval Follow-up Evaluation (LIFE) and the Hamilton Rating Scale for Depression (HRSD) (Through month 18 of treatment); Number of Participants in Recovery According to the LIFE and HRSD (Through 36 months of treatment); Number of Participants in Recurrence According to the LIFE and HRSD (Measured up to Month 36 from recovery)
B: Changes in Neuropsychiatric Inventory (24 weeks); Changes in Cornell's Depression Scale (24 weeks); Changes in UPDRS subscale (24 weeks)
C: Number of patients who fully discontinued their antidepressant medication after 6 months. (6 months)
D: Hamilton Rating Scale for Anxiety (Measured at Months 6 (Open Label), 12 (Double-Blind), and 18 (Double-Blind Relapse))

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Primary Care in Patients With Mental Disorders
Brief Summary: This study will determine the effectiveness of medical case management in improving the medical care of people with mental disorders or substance abuse problems.


Options:
A: Penn State Worry Questionnaire-Abbreviated (Week 11)
B: Number of patients reported to the Ontario Ministry of Transportation (When participants have completed 500 patient assessments (expected to take approximately 12 months))
C: Decisional conflict regarding the treatment for Generalized Anxiety Disorder, measured by the Decisional Conflict Scale (DCS) (Change from Baseline at 3 months after intervention)
D: Quality of primary medical care (Measured over 2 years)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Primary Care in Patients With Mental Disorders
Brief Summary: This study will determine the effectiveness of medical case management in improving the medical care of people with mental disorders or substance abuse problems.


Options:
A: Hemoglobin A1c (6 months)
B: SF-12 MCS (6-Month Follow-up)
C: Quality of primary medical care (Measured over 2 years)
D: Severity of depression symptoms

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Treating PTSD in Children Exposed to Domestic Violence
Brief Summary: This study will determine whether trauma-focused cognitive behavioral therapy (TF-CBT) is more effective than child-centered therapy (CCT) in reducing post traumatic stress disorder (PTSD) in children exposed to domestic violence (DV).


Options:
A: PTSD symptoms (Measured before and after treatment and Months 6 and 12 of follow-up); Anxiety (Measured before and after treatment and Months 6 and 12 of follow-up); Depression (Measured before and after treatment and Months 6 and 12 of follow-up); Behavior (Measured before and after treatment and Months 6 and 12 of follow-up)
B: Time Line Follow Back and urine screen (Pre and post-treatment, 3 and 6 month follow-ups)
C: Change in post-traumatic stress symptoms measured by UCLA-PTSD-RI (Post-intervention and 3 month)
D: Change in scores on the Oxford Measure of Psychosocial Adjustment & World Health Organization Disability Assessment Schedule, 2.0 (WHODAS 2.0) (Administered at 4 timepoints: (1) baseline; (2) within 15 days of YRI completion; (3) 6 months post-YRI; (4) 12 months post-YRI)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Placebo-controlled Trial of Fluoxetine in Preschool Children
Brief Summary: This study is a pilot study to evaluate the feasibility and safety of conducting a year long, double-blind, placebo-controlled trial of fluoxetine in pre-school children to enhance developmental processes in core areas impacted by autism.


Options:
A: Rate of Recruitment (19 months)
B: Change from baseline Home Situations Questionnaire-Autism Spectrum Disorder (HSQ-ASD) score, at three months. Within subject difference between the placebo condition and the whole plant extract condition. (At onset of each treatment period, at 1 month, 2 months and 3 months (end of treatment period)); Clinical Global Impression-Improvement scores (CGI-I ) at three months. Within subject difference between the placebo condition and the whole plant extract condition. (At 3 months (end of treatment period))
C: Clinical Global Impression-Improvement (Change from baseline to end of week 12); Aberrant Behavior Checklist- Irritability (Change between baseline and end of each phase)
D: Effect of Arbaclofen vs. placebo on social function (Week 0 + Week 16)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Placebo-controlled Trial of Fluoxetine in Preschool Children
Brief Summary: This study is a pilot study to evaluate the feasibility and safety of conducting a year long, double-blind, placebo-controlled trial of fluoxetine in pre-school children to enhance developmental processes in core areas impacted by autism.


Options:
A: Change From Baseline in Aberrant Behavior Checklist Irritability Subscale (ABC-I) (Baseline and 7 days.)
B: Social Responsiveness Scale (SRS) Change (Completed at Baseline and Week 11); Social Responsiveness Scale (SRS) at Follow-Up (Completed at Week 22)
C: Change From Baseline in Parent Rated Social Responsiveness Scale, 2nd Edition (SRS-2) T-Score After Treatment. (Baseline; Week 4)
D: Rate of Recruitment (19 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Placebo-controlled Trial of Fluoxetine in Preschool Children
Brief Summary: This study is a pilot study to evaluate the feasibility and safety of conducting a year long, double-blind, placebo-controlled trial of fluoxetine in pre-school children to enhance developmental processes in core areas impacted by autism.


Options:
A: Change in Aberrant Behavior Checklist Irritability (ABC-I) Subscale (Baseline and 6 weeks)
B: Rate of Recruitment (19 months)
C: Clinical Global Impression-Improvement Scale (CGI-I) (Baseline to 12 weeks)
D: Core autistic symptoms (ATEC) (Once every 4 weeks during the first three mounth); Side effects and adverse events questionnaire (Once every 4 weeks during the first phase(12 weeks))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Depression Prevention Program for High-Risk Adolescents
Brief Summary: This study will compare the effectiveness of two programs designed to prevent depression in adolescents.


Options:
A: Depressive symptoms (Pre-, post-monitoring, 6-week follow up & 6 month follow-up); Emotional Self Awareness (Pre-, post-, 6-weeks post- and 6-months post-test)
B: psychological symptoms (6 months); coping (6 months)
C: Presence or absence of a depressive episode (child) (T4 (9 months after completion of the programme))
D: Depressive symptoms (Measured at Year 1)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: scl-90-R, IIP-C, GAF (before and after therapy,follow-up and every 3 months during therapy)
B: Suicidal thoughts or attempts (Measured at Year 2)
C: Borderline Symptom Checklist (BSL-23) (Changes in scores of BSL-23 before treatment, and at 4, 8, 12 months after starting the treatment)
D: Suicidal behaviour (2-year follow-up); Suicidal behaviour (1-year follow-up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: PTSD Symptoms (CAPS, SCID, PDS, IESR) (1.5 years)
B: Zanarini Rating Scale for Borderline Personality Disorder (Change from baseline through weeks 2-12, 6 month follow-up, 9 month follow-up, 12 month follow-up)
C: Borderline Symptoms (6 weeks)
D: Suicidal thoughts or attempts (Measured at Year 2)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: Change in BPD (Borderline Personality Disorder) behaviors (8-weeks)
B: Suicidal thoughts or attempts (Measured at Year 2)
C: Suicide ideation (12 month)
D: suicidal ideation - Suicidal Ideation Questionnaire-JR (3 month)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: Suicidal thoughts or attempts (Measured at Year 2)
B: Repeat Suicide Attempts (1, 2, and 3 months)
C: Beck Depression Inventory (V2) (Baseline to 6 months)
D: suicidal ideation - Suicidal Ideation Questionnaire-JR (3 month)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: Change from baseline Perceived Stress Scale (PSS) score at 4, 8 weeks (Baseline and after 4, 8 weeks later)
B: Change from baseline compassion fatigue at 1 and 6 months assessed by compassion fatigue subscale of Professional quality of life scale (Data collected before the program starts and one months after the end of the program and six months); Change from baseline burnout at 1 and 6 months assessed by burnout subscale of Professional quality of life scale (Data collected before the program starts (pretest) and one months after the end of the program and six months); Change from baseline compassion satisfaction at 1 and 6 months assessed by compassion satisfaction subscale of Professional quality of life scale (Data collected before the program starts (pretest) and one months after the end of the program and six months)
C: Suicidal thoughts or attempts (Measured at Year 2)
D: Frequency of subsequent episodes of deliberate self harm and time elapsed to future episodes of deliberate self harm (16 weeks and 68 weeks); Severity of suicidal ideation, level of depressive symptoms (16 weeks and 68 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: Suicidal thoughts or attempts (Measured at Year 2)
B: Psychosocial functioning (The outcomes will be assessed after 8, 18, 36, and 72 months:); symptom distress (after 8, 18, 36 and 72 months); self esteem (after 8, 18, 36 and 72 months); interpersonal problems, (after 8, 18, 36 and 72 months); self destructive behavior, (after 8, 18, 36 and 72 months); personality pathology, (after 36 and 72 months); quality of life, (after 8, 18, 36 and 72 months); health care utilization after (after 8, 18, 36 and 72 months)
C: scl-90-R, IIP-C, GAF (before and after therapy,follow-up and every 3 months during therapy)
D: Change on the severity of borderline personality disorder measured by Borderline Personality Symptom List (BSL-23). (Baseline and up to 12 months after inclusion.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Assessment and Treatment of Parasuicidal Patients
Brief Summary: This study is a component analysis of dialectical behavior therapy (DBT) to determine the importance of DBT skills training and DBT individual therapy in treating suicidal women with borderline personality disorder.


Options:
A: Number of suicide re-attempters (six months)
B: Suicidal thoughts or attempts (Measured at Year 2)
C: Persons repeating a suicidal act (One, two and three years)
D: First recurrent suicide behavior (suicide attempted and completed suicide) (Minimum 1.5 year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Prophylactic Cognitive Therapy for Depression.
Brief Summary: This study determined the effectiveness of continuation phase cognitive therapy versus antidepressant medication in preventing relapse of depression in people with recurrent depression.


Options:
A: Depressive Relapse or MDD (Measured at month 8); Depressive Relapse/Recurrence or MDD (Measured at month 20); Depressive Relapse/Recurrence or MDD (Measured at month 32)
B: Depressive symptoms as measured by the HRSD (24-item Hamilton Rating Scale of Depression) (20 weeks after randomization (after acute treatment phase))
C: Relapse/recurrence of Major Depressive Episode (3, 6, 9, 12, 15 months)
D: N/A

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Treating Terror-Related PTSD in Adolescents
Brief Summary: This study will compare the effectiveness of prolonged exposure therapy versus active psychotherapy in treating post-traumatic stress disorder (PTSD) in adolescents.


Options:
A: Score on Harvard Traume Questionnaire (PTSD) (before entry, after 6 months treatment and at follow up)
B: Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) (2 weeks after the first infusion)
C: Symptoms of post-traumatic stress disorder (Measured at Month 3); Symptoms of depression (Measured at Month 3)
D: Changes in CAPS Scores. (Baseline, 8 weeks)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use
Brief Summary: The purpose for this study is to determine whether 2x45 minutes Motivational Interviewing given during hospital stay to acutely admitted psychiatric patients with substance use problems, can reduce substance use after discharge.


Options:
A: The Number of Alcohol Drinks Per Week (as Measured by the Time Line Follow Back Procedure) at the 6 Month Follow-up. (6-months); Percent Days Abstinent From Alcohol at 6 Months (6-months)
B: Substance use and function questionnaire (2 years)
C: Alcohol consumption in the last 30 days, assessed at baseline and repeatedly during follow-up so that change can be analyzed. (Baseline, 30, 60 days (end-of-treatment), 3, 6, 12 months)
D: Drug use (Six Months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Motivational Interviewing to Acutely Admitted Psychiatric Patients With Comorbid Substance Use
Brief Summary: The purpose for this study is to determine whether 2x45 minutes Motivational Interviewing given during hospital stay to acutely admitted psychiatric patients with substance use problems, can reduce substance use after discharge.


Options:
A: Substance use and function questionnaire (2 years)
B: longest continuous period of cocaine abstinence (Week 8)
C: Cannabis use reduction in the follow-up (Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up.); Improvement in the development of psychotic disorder (Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up); Changes in the components of the endogenous cannabinoid system (Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up); Normalizing the possible alterations in the endogenous cannabinoid system (Baseline, 16 weeks (posttreatment), at 3 and 6 months and at one year of follow up)
D: Stimulant drug use as measured by urine analysis (Treatment phase: 12 weeks (3 measurements a week), Follow Up Phase: 3 months (1 measuresment a month))

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: Psychotic symptoms at one and two year follow-up; Negative symptoms at one and two year follow-up
B: Functioning (social and occupational) (baseline, 12-month)
C: Prognosis of patients. (6 months)
D: Rehospitalizations and psychotic relapse at two years

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: Functioning (social and occupational) (baseline, 12-month)
B: Rehospitalizations and psychotic relapse at two years
C: USCD Performance-Based Skills Assessment (2009)
D: Psychotic symptoms at one and two year follow-up; Negative symptoms at one and two year follow-up

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: Functioning (social and occupational) (baseline, 6-month, 12-month, 24-month, 36-month, 48-month)
B: Relapses (9 months); Positive and negative symptoms (change from baseline at 9 month follow-up)
C: Rehospitalizations and psychotic relapse at two years
D: Psychotic symptoms at one and two year follow-up; Negative symptoms at one and two year follow-up

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Continued Early Intervention for Recent-onset Schizophrenia. A Randomized Controlled Study.
Brief Summary: The purpose of this study was to determine whether outreach integrated treatment of first episode schizophrenia was more effecive than standard outpatient treatment.


Options:
A: relapse rate (1 year)
B: Rehospitalizations and psychotic relapse at two years
C: Clinical Global Impression every 2 weeks; Simpson and Angus Rating Scale for Extrapyramidal Effects every 2 weeks; Barnes Rating Scale for Drug-Induced Akathisia every 2 weeks; Abnormal Involuntary Movement Scale every 2 weeks; Drug Attitude Inventory every 2 weeks; Calgary Depression Scale for Schizophrenia every 2 weeks; Brief Psychiatric Rating Scale every 2 weeks
D: relapse rate (1 year)

Answer: B